임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 24-06-18 08:16
논문번호 286
논문제목(영문) Angiotensin Converting Enzyme Inhibitors versus Angiotensin II type 1 Receptor Blockers in Patients with Acute Myocardial Infarction and Prediabetes after Successful Implantation of Newer-Generation Drug-Eluting Stents.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Kim YH
교신저자명 Kim YH
공동저자명 Her AY, Jeong MH, Kim BK, Hong SJ, Park SH, Kim S, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y
게제년월일 2023-01-01
ISSN 1897-5593
Impact Factor 3.0
학술지명 Cardiol J
서지사항 0집 / 30권 / 4호,   페이지(614 - 626)
요약초록문
(Abstract) 입력		 Background: Because limited data are available, the present study investigated 2-year major clinical outcomes after angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) therapy in patients with acute myocardial infarction (AMI) and prediabetes after successful implantation of newer-generation drug-eluting stents (DESs).

Methods: Overall, 2932 patients with AMI and prediabetes were classified into two groups - the ACEIs group (n = 2059) and the ARBs group (n = 873). The primary endpoint was the occurrence of patient- -oriented composite outcome (POCO), defined as all-cause death, recurrent myocardial infarction (Re-MI), or any repeat revascularization. The secondary endpoint was definite or probable stent thrombosis (ST).

Results: The cumulative incidences of POCO (adjusted hazard ratio [aHR]: 1.020; 95% confidence interval [CI]: 0.740-1.404; p = 0.906), all-cause death (aHR: 1.394; 95% CI: 0.803-2.419; p = 0.238), Re-MI (aHR: 1.210; 95% CI: 0.626-2.340; p = 0.570), any repeat revascularization (aHR: 1.150; 95% CI: 0.713-1.855; p = 0.568), and ST (aHR: 1.736; 95% CI: 0.445-6.766; p = 0.427) were similar between the groups. These results were confirmed after propensity score-adjusted analysis.

Conclusions: In this study, patients with AMI and prediabetes who received ACEIs or ARBs showed comparable clinical outcomes during the 2-year follow-up period.
파일  C286.pdf (287.7K) DATE : 2024-06-18 08:16:54